| Dataset ID | Technology | Samples |
|---|---|---|
| EGAD00001003923 | Illumina HiSeq 2500 | 15 |
Dataset Description
The discovery of the BRAF V600E mutation in almost all cases of hairy-cell leukemia has led to the widespread adoption of the BRAF inhibitor vemurafenib for treatment of chemotherapy-resistant cases. Impressive responses are reported; however, acquired resistance is common. Whilst diverse mechanisms of vemurafenib resistance have been elucidated in melanoma, the basis of resistance in HCL is unclear. Here we apply whole genome and deep targeted sequencing to investigate resistance mechanisms and potential therapeutic strategies in a patient with aquired resistance to vemurafenib.
Data Use Conditions
IS PUB US
See further information on Data Use Conditions
| Label | Code | Version | Modifier |
|---|---|---|---|
| general research use | DUO:0000042 | 2021-02-23 | |
| institution specific restriction | DUO:0000028 | 2021-02-23 | |
| publication required | DUO:0000019 | 2021-02-23 | |
| user specific restriction | DUO:0000026 | 2021-02-23 |
